Insider Buying: Catalyst Pharmaceutical Partners Director Acquires 8,000 Shares of Stock (CPRX)
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Director David Tierney acquired 8,000 shares of the stock on the open market in a transaction that occurred on Wednesday, October 23rd. The stock was purchased at an average price of $2.03 per share, with a total value of $16,240.00. Following the completion of the acquisition, the director now directly owns 213,401 shares of the company’s stock, valued at approximately $433,204. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
CPRX has been the subject of a number of recent research reports. Analysts at Aegis raised their price target on shares of Catalyst Pharmaceutical Partners from $4.00 to $5.50 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Catalyst Pharmaceutical Partners from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, October 18th. They now have a $3.10 price target on the stock. Finally, analysts at Zacks reiterated a “hold” rating on shares of Catalyst Pharmaceutical Partners in a research note to investors on Wednesday, October 16th. They now have a $1.00 price target on the stock.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded down 3.11% during mid-day trading on Friday, hitting $1.87. 1,584,176 shares of the company’s stock traded hands. Catalyst Pharmaceutical Partners has a 52 week low of $0.37 and a 52 week high of $2.75. The stock’s 50-day moving average is $1.64 and its 200-day moving average is $0.98. The company’s market cap is $77.5 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Analysts expect that Catalyst Pharmaceutical Partners will post $-0.24 EPS for the current fiscal year.
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.